Physician profile
Randy B Powell
NPI 1609824770
$2,585.26
in general payments reported to CMS, 2019-2025
24 companies · $30.14 in 2025
The $30.14 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,311 · 2020: $172 · 2021: $100 · 2022: $292 · 2023: $258 · 2024: $422 · 2025: $30.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $340.84 | 2019-2024 | Breztri |
| Amgen INC. | $301.38 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $279.04 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $277.82 | 2019-2024 | |
| Astellas Pharma US INC | $190.37 | 2019-2020 | |
| Lilly USA, LLC | $165.06 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Therapeuticsmd, INC. | $157.28 | 2019 | |
| Exact Sciences Corporation | $151.44 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $118.34 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $114.46 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $108.31 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.14 | 2019 | |
| Stryker Corporation | $50.77 | 2022 | |
| Dexcom, INC. | $40.95 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $31.44 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.44 | 2019-2024 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $20.89 | 2019 | |
| Phadia US INC. | $16.89 | 2024 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.66 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.55 | 2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $15.52 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $14.75 | 2019 | |
| Vivus LLC | $13.63 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.